NFKB1 and metabolic dysfunction-associated steatohepatitis: Consistent with the reduced ALT and TG levels, atorvastatin-treated NASH animals showed significant attenuation of macrovesicular liver steatosis and inflammatory cell infiltration as detected by histological evaluation and by the significantly reduced NF-κB p65, and F4/80 protein expression levels (Figure 2).